3：新药资讯第30期商业动态篇(2017.12.08-2017.12.14)

新药资讯第30期商业动态篇(2017.12.08—12.14)摘要本周完成IPO的公司有3家，分别是美国新兴生物技术公司Denali Therapeutics、美国癌症疗法研究公司Odonate Therapeutics和法国制药公司Advicenne Pharma；宣布IPO的公司有2家，分别是美国新药研发公司resTORbio和中国苏轩堂药业。

Mallinckrodt 1.17亿美元完成对Ocera Therapeutics 100％股权的收购。

本周完成A轮融资的有6家，分别是中国生物技术公司三叶草生物制药获得950万美元、荷兰生物技术公司NorthSea Therapeutics获得2946万美元、比利时生物结构修饰公司Aelin获得3177万美元、美国生物技术公司Obsidian Therapeutics获得4950万美元、美国制药公司Neumentum获得600万美元、美国生物技术公司Lumen Bioscience获得1120万美元；完成B轮融资的有1家，美国生物技术公司Metacrine获得2200万美元；完成C轮融资的有1家，奥地利生物技术公司Hookipa Biotech获得5960万美元。

IPO（5）1. 美国生物技术公司Denali Therapeutics完成2.87亿美元IPO，DenaliTherapeutics（纳斯达克：DNLI）是一家美国新兴的生物技术公司，致力于神经退行性疾病治疗药物的开发，主要针对阿尔兹海默症（AD）、帕金森症和肌萎缩侧索硬化（ALS），本次IPO以每股18美元的价格，累计公开发行15,972,221股普通股票，其中包括承销商以每股18美元购买的2,083,333股，总收益达2.8749亿美元。

Goldman Sachs & Co. LLC、Morgan Stanley & Co. LLC 和J.P. Morgan Securities LLC 担任本次发行的承销商代表，Evercore Group L.L.C. 担任本次发行的承销商。

2. 美国癌症疗法研究公司Odonate Therapeutics完成总收益1.5亿美元的IPO。

Odonate Therapeutics LLC（纳斯达克，ODT）是一家总部位于美国的新型成长型公司，致力于开发改善和延长癌症患者生命的一流疗法。

本次IPO 以每股24美元价格公开发行625万普通股，总收益1.5亿美元，Goldman Sachs & Co. LLC，Jefferies LLC 和Cowen and Company, LLC担任本次发行的承销商代表。

3.法国制药公司Advicenne Pharma完成总收益3202万美元的IPO，Advicenne是法国的一家制药公司，致力于为患有癫痫以及肾或孤儿病等神经疾病的儿童患者开发药物。

本次IPO是在巴黎泛欧证券交易所，股票代码为ADVIC，以每股14.03欧元的价格公开发行1,924,448股新股，总收益2700万欧元（合计3202万美元），SGD和NIBC Bank N.V.担任联合全球协调人，联合领投经办人和联合账簿管理人。

4. 美国新药研发公司resTORbio宣布将首次公开募股（IPO），resTORbio是一家美国的新药研发公司，致力于与衰老有关疾病药物的开发，已经向美国证券交易委员会提交了S-1版的IPO注册声明草案，关于发行股数，价格等暂未公开。

5. 中国SXT 制药宣布将赴纳斯达克IPO，China SXT Pharmaceuticals, Inc.是一家位于中国的制药公司，宣布已向美国证券交易委员会提交IPO注册声明，首次公开发行普通股，计划募集资金总额1500万美元。

股票价格、发行承销商等暂未公开。

企业并购（１）1. Mallinckrodt 1.17亿美元完成对Ocera Therapeutics 100％股权的收购，Mallinckrodt plc是一家总部位于爱尔兰的专业制药公司，Ocera Therapeutics，Inc.是一家美国的临床阶段的生物制药公司，两家公司已达成协议，Mallinckrodt以每股1.52美元（约合4200万美元）的价格收购Ocera Therapeutics，Inc.已发行所有股票，加上Ocera Therapeutics有权以成功完成某些成果和销售里程碑为基础，以每股2.58美元（高达约7500万美元）的现金收取一笔或多笔款项。

融资（8）1. 中国生物技术公司三叶草生物制药完成了6280万元人民币(约950亿美元)首轮融资，本轮融资领投为天河生命科学的风险基金。

三叶草生物制药是一家全球性临床试验阶段的生物制药公司，致力于创新药及高端生物类似药的研发和产业化，重点领域为肿瘤治疗和自身免疫性疾病。

三叶草采用其独有的Trimer-Tag©（蛋白质三聚体化）技术平台，研发依赖于三聚体功能结构的靶向三聚体化创新生物制药；同时，三叶草利用其自身cGMP大分子生物制药生产能力，选择性地开发高端生物类似药。

2. 荷兰生物技术公司NorthSea Therapeutics获得2946万美元的A轮融资。

该轮融资由Forbion Capital Partners领投，其他投资者包括Benhamou Global Ventures、LLC (BGV)等。

NorthSea Therapeutics B.V.,是一家位于荷兰的生物技术公司，公司将利用该笔资金进行icosabutate在NASH（代表炎症和对肝脏的损害）患者中的临床IIb研究，将icosabutate的临床研究推至临床III期阶段，还包括临床和非临床的毒性研究和CMC开发。

3. 比利时生物结构修饰公司Aelin获得了3177万美元的A轮融资。

本轮融资总额2700万欧元（和3177万美元），投资者包括Life Sciences Partners (LSP)、PMV nv (ParticipatieMaatschappij Vlaanderen)、Novartis Venture Fund、Boehringer Ingelheim Venture Fund 和Fund+。

Aelin Therapeutics是总部位于比利时的生物治疗公司，由VIB及其合作大学KU Leuven，VUB和UGent 创立，致力于著名生物结构学家Joost Schymkowitz教授和Frederic Rousseau教授的生物结构开创性工作，Aelin打算利用融资收益开发其专有的Pept-in （TM）蛋白质敲除平台。

4. 美国生物技术公司Obsidian Therapeutics获得4950万美元A轮融资，该轮融资由Google Ventures (GV)领投，其他投资者包括Atlas Venture、Takeda Ventures Inc.、Vertex Ventures HC、Amgen Ventures、Alexandria Venture Investments和ShangPharma Investment Group。

Obsidian Therapeutics是一家位于美国的生物技术公司，致力于开发下一代细胞和基因疗法，公司打算利用这笔资金进一步建立技术平台，并将其主要项目推向临床开发。

5. 美国制药公司Neumentum获得600万美元A轮融资，Brookline Capital Markets作为本轮融资的独家代理人。

Neumentum正在开发并计划将有效治疗疼痛的产品商业化，其镇痛药无阿片类镇痛剂的滥用，误用和成瘾性的风险。

Neumentum公司的主要候选药物NTM-001（预混合酮咯酸连续输注）和NTM-002（IV患者自控镇痛）有可能在缓解疼痛上与阿片类药物药效相当，减少临床情况下对阿片类药物的需求。

6. 美国生物技术公司Lumen Bioscience获得1120万美元A轮融资。

投资者包括Avista Development, Inc.、BioEconomy Capital、Brian Finrow和其他西雅图地区生物技术投资者，同时公司也获得美国能源部给予的180万美元的资助，用于推出生物技术产品开发平台。

7. 美国生物技术公司Metacrine获得2200万美元B轮融资。

本轮融资由New Enterprise Associates (NEA)领投，其他投资者包括ARCH、Polaris、venBio 和Alexandria Venture Investments。

Metacrine计划利用该笔资金将其主要候选化合物MET409（一种口服非胆汁酸FXR激动剂）推到IND阶段的后期研究。

Metacrine是一家总部位于加利福尼亚州圣地亚哥的私人生物技术公司，致力于开发治疗代谢性疾的创新药物。

8. 奥地利生物技术公司Hookipa Biotech获得5960万美元C轮融资。

由未披露的blue chip U.S. public investment fund领投，其他投资者包括HBM Partners AG、Hillhouse Capital Management、Sirona Capital、Gilead Sciences, Inc.和Sofinnova Partners等。

Hookipa是位于奥地利的临床阶段的生物技术公司，将利用该笔资金进行实体器官移植患者中预防性巨细胞病毒（“CMV”）感染疫苗的II期研究，以及一项基于主动免疫的TheraT（R ）疗法用于头颈部鳞状细胞癌患者。

此外，Hookipa还计划将其技术平台扩展到其他疾病领域，如前列腺癌。

更多详情请关注wei xin：New Drugs Business Intelligence (12/08/2017—12/14/2017)IPO1. Denali Therapeutics closes $287.49 million initial public offering (IPO)Denali Therapeutics, Inc., (NASDAQ:DNLI) a US-based biotechnology company, has closed its initial public offering (IPO) of 15,972,221 million shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase up to 2,083,333 additional shares, at a price of $18 per share, for the gross proceeds of $287.49 million.Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC are acting as representatives of the underwriters for the offering. Evercore Group L.L.C. is acting as underwriter for the offering.2. Odonate Therapeutics closes initial public offering (IPO) Odonate Therapeutics LLC, a US-based pharmaceutical company, has closed its initial public offering of 6.25 million shares of common stock at a price of $24 per share, for gross proceeds of $150 million. Goldman Sachs & Co. LLC, Jefferies LLC and Cowen and Company, LLC are acting as representatives of the underwriters for the offering.Odonate Therapeutics™ is dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. The Company’s initial focus is on the development of tesetaxel, a novel, orally administered chemotherapy belonging to the taxane class. Odonate’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.3. Advicenne Pharma raises $32.02 million in IPOAdvicenne Pharma, a France-based specialist pharmaceutical company focused on the development of paediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases, has raised EUR27 million through an issue of 1,924,448 new shares at a price of EUR14.03 per share in an initial public offering (IPO).Advicenne has granted Societe de bourse Gilbert Dupontan (SGD) an overallotment option that can be exercised from December 5, 2017 until January 4, 2018 (inclusive) for up to a maximum of 83,270 additional new shares to be issued in case of exercise of the overallotment option. Advicenne lists its shares under the symbol ‘ADVIC’ with Euronext Paris. SGD and NIBC Bank N.V. acted as joint global coordinators, joint lead managers and joint book-runners for the offering.4. resTORbio announces initial public offering of common stock resTORbio, Inc., a US-based developer of medicines to treat aging-related diseases and conditions, intend to offer initial public offering of its common stock.resTORbio, Inc. announced that it has previously confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to commence after the SEC completes its review process, subject to market and other conditions.5. China SXT Pharmaceuticals announces initial public offering (IPO) China SXT Pharmaceuticals, Inc., a China-based pharmaceuticals company, has filed a registration statement with the US Securities Exchange Commission (SEC) for an initial public offering (IPO) of shares of its common stock to raise aggregate gross proceeds of $15 million. We have reserved the symbol “ “ for purposes of listing our Ordinary Shares on the NASDAQ Capital Market (“NASDAQ”) and plan to apply to list Ordinary Shares on that exchange.We estimate that we will receive net proceeds from this offering, after deducting the estimatedunderwriting discounts and commissions and the estimated offering expenses payable by us and based upon an assumed initial public offering price of US$ per Ordinary Share, of approximately $ if we sell [ ] number of Ordinary Shares.M&A1. Mallinckrodt acquires 100% stake in Ocera Therapeutics Mallinckrodt plc, an Ireland-based specialty pharmaceutical company, has acquired all of the outstanding shares of Ocera Therapeutics, Inc., a US-based clinical stage biopharmaceutical company.Mallinckrodt plc, an Ireland-based specialty pharmaceutical company, has entered into an agreement to acquire all of the outstanding shares of Ocera Therapeutics, Inc., a US-based clinical stage biopharmaceutical company, for $1.52 per share (approximately $42 million), plus one contingent value right to receive one or more payments in cash of up to $2.58 per share (up to approximately $75 million) based on the successful completion of certain development and sales milestones.Venture Financing1. Clover Biopharmaceuticals Completes US$9.5m in Series AFinancingClover Biopharmaceuticals, a Chengdu, China-based biotechnology company focused on developing novel and transformative biologic therapies, completed a RMB 62.8m (approximately US$9.5m) Series A financing.The Series A round was led by Tianhe Life Sciences Venture Fund. Combined with other nondilutive sources of funding, this financing brings Clover’s total cash proceeds received in 2017 to RMB 84.3m (approximately US$ 12.7m).2. NorthSea Therapeutics secures $29.46 million in Series A financing NorthSea Therapeutics B.V., a Netherlands-based biotechnology company, has raised EUR25 million in Series A financing led by Forbion Capital Partners and Benhamou Global Ventures, LLC (BGV) includes Novo Seeds, the early-stage investment arm of Novo Holdings A/S and New Science Ventures.NorthSea intends to use the proceeds to conduct a phase IIb clinical study in NASH with icosabutate and to develop it to phase III readiness, including clinical and non-clinical toxicology studies and CMC development.3. Aelin Therapeutics raises $31.77 million in Series A financing Aelin Therapeutics, a Belgium-based biotherapeutics company, has raised EUR27 million in Series A financing from Life Sciences Partners (LSP), PMV nv (ParticipatieMaatschappij Vlaanderen), Novartis Venture Fund, Boehringer Ingelheim Venture Fund and Fund+.Aelin Therapeutics is founded by VIB and its partner universities KU Leuven, VUB and UGent, based on the groundbreaking work of renowned structural biologists Prof Joost Schymkowitz and Prof Frederic Rousseau. Aelin intends to use the proceeds to exploit its proprietary Pept-in(TM) protein knockdown platform.4. Obsidian Therapeutics raises $49.5 million in Series A financing Obsidian Therapeutics, Inc., a US-based biotechnology company dedicated to the development of next-generation cell and gene therapies with pharmacologic operating systems, has raised $49.5 million Series A financing was led by Google Ventures (GV), with participation from Atlas Venture, as well as Takeda Ventures Inc., Vertex Ventures HC, Amgen Ventures, Alexandria Venture Investments, and ShangPharma Investment Group.Obsidian Therapeutics intends to use the proceeds to further build its technology platform and advance its lead programs toward clinical development.5. Neumentum secures $6 million in Series A funding Neumentum, a US-based pharmaceutical company, has secured $6 million in Series A funding. Brookline Capital Markets acted as the exclusive placement agent for the funding.Neumentum is developing and plans to commercialize products that effectively treat pain, without the risks of abuse, misuse and diversion seen with opioid analgesics. Neumentum’s lead product candidates, NTM-001 (pre-mixed bag ketorolac continuous infusion) and NTM-002 (IV patient-controlled analgesia) have potential to maintain pain relief at an opioid level, reducing the need for opioids in clinical settings.6. Lumen Bioscience secures $11.2 million in Series A funding Lumen Bioscience, Inc., a US-based synthetic biotechnology company developing a novel bio-based product development platform, has secured $11.2 million in Series A funding from Avista Development, Inc., BioEconomy Capital, Brian Finrow and other Seattle-area biotech investors. Lumen will use the funds to launch a new biotech production platform.Concurrently, Lumen Bioscience has received $1.8 million in grant from the US Department of Energy for the launch of a biotech product development platform.7. Metacrine raises $22 million in Series B financingMetacrine, Inc., a US-based biotechnology company focused on drug development, has raised $22 million in Series B financing was led by New Enterprise Associates (NEA), with participation from existing investors ARCH, Polaris, venBio, and Alexandria Venture Investments.Metacrine intends to use the funds to continue to advance its lead asset, MET409, an oral non-bile acid FXR agonist, into late stage IND-enabling studies. Metacrine is a privately held biotechnology company headquartered in San Diego, CA. The company is focused on efficiently developing innovative drugs that materially benefit patients with metabolic disease.8. Hookipa Biotech secures $59.6 million in Series C funding Hookipa Biotech AG, an Austria-based clinical stage biotechnology company, has raised $59.6 million in a Series C funding led by an undisclosed blue chip U.S. public investment fund, with participation from HBM Partners AG, Hillhouse Capital Management, Sirona Capital, Gilead Sciences, Inc., Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures, Inc. and BioMedPartners AG.Hookipa will use the proceeds to progress two proof-of concept clinical trials of its lead development programs, a phase II study of itsprophylactic Cytomegalovirus (“CMV”) vaccine in solid organ transplant patients, and a phase I study of its TheraT(R) based active immunization therapy in patients with head & neck squamous cell carcinoma. In addition, Hookipa plans to expand its technology platform into other disease areas, such as prostate cancer.编辑：Kelly/Sophia图片：网络声明：本文由新药创投俱乐部小编整理，欢迎交流补充，转载请注明出处。